ORIGINAL RESEARCH

Persistence of Serotonergic Enhancement of Airway Response in a Model of Childhood Asthma

Brian D. Moore[1], Dallas M. Hyde[2], Lisa A. Miller[2], Emily M. Wong[2], and Edward S. Schelegle[2]

[1]University of the Pacific, Stockton, California; and [2]California National Primate Research Center, Respiratory Diseases Unit, University of California Davis, Davis, California

Abstract

The persistence of airway hyperresponsiveness (AHR) and serotonergic enhancement of airway smooth muscle (ASM) contraction induced by ozone (O_3) plus allergen has not been evaluated. If this mechanism persists after a prolonged recovery, it would indicate that early-life exposure to O_3 plus allergen induces functional changes predisposing allergic individuals to asthma-related symptoms throughout life, even in the absence of environmental insult. A persistent serotonergic mechanism in asthma exacerbations may offer a novel therapeutic target, widening treatment options for patients with asthma. The objective of this study was to determine if previously documented AHR and serotonin-enhanced ASM contraction in allergic monkeys exposed to O_3 plus house dust mite allergen (HDMA) persist after prolonged recovery. Infant rhesus monkeys sensitized to HDMA were exposed to filtered air (FA) ($n = 6$) or HDMA plus O_3 ($n = 6$) for 5 months. Monkeys were then housed in a FA environment for 30 months. At 3 years, airway responsiveness was assessed. Airway rings were then harvested, and ASM contraction was evaluated using electrical field stimulation with and without exogenous serotonin and serotonin-subtype receptor antagonists. Animals exposed to O_3 plus HDMA exhibited persistent AHR. Serotonin exacerbated the ASM contraction in the exposure group but not in the FA group. Serotonin subtype receptors 2, 3, and 4 appear to drive the response. Our study shows that AHR and serotonin-dependent exacerbation of cholinergic-mediated ASM contraction induced by early-life exposure to O_3 plus allergen persist for at least 2.5 years and may contribute to a persistent asthma phenotype.

Keywords: serotonin; ozone; antigens; hyperresponsiveness; *Macaca mulatta*

Clinical Relevance

Airway hyperresponsiveness and serotonin-dependent exacerbation of cholinergic-mediated airway smooth muscle contraction induced by early-life exposure to ozone plus allergen persist for at least 2.5 years and may contribute to a persistent asthma phenotype. These findings substantiate the need to minimize exposure of young individuals to known environmental contributors to asthma during critical periods of lung maturation because damage inflicted during these times can contribute to prolonged asthma symptoms. The identification of a persistent 5-HT–mediated enhanced airway smooth muscle contraction may identify novel therapeutic targets for pharmacological intervention in the treatment of childhood asthma.

Asthma is one of the most common chronic childhood conditions in the United States. In 2011, ~ 7 million children suffered from asthma (1). The most frequent reason for school absences is asthma, accounting for one third of school days missed, and the severity of symptoms is negatively correlated with achievement (2).

The link between ozone (O_3) and house dust mite allergen (HDMA) exposure and childhood asthma has been supported by a wealth of research (3–9). In the latest State of the Air report, almost half of United States citizens—over 148 million people—live in areas with unhealthy O_3 levels (6).

Although the mechanisms responsible for asthma symptoms are debatable, research shows that O_3 and HDMA

(Received in original form September 6, 2013; accepted in final form January 23, 2014)

This research was supported by a National Institute of Health Sciences Program Project grant P01ES000628–33.

Author Contributions: Conception and design: D.H., L.M., E.S., B.M. Analysis and interpretation: E.S., B.M., E.W. Drafting the manuscript for important intellectual content: B.M., E.S.

Correspondence and requests for reprints should be addressed to Edward Schelegle, Ph.D., Anatomy, Physiology & Cell Biology, University of California–Davis, Davis, CA 95616. E-mail: esschelegle@ucdavis.edu

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org

Am J Respir Cell Mol Biol Vol 51, Iss 1, pp 77–85, Jul 2014
Copyright © 2014 by the American Thoracic Society
Originally Published in Press as DOI: 10.1165/rcmb.2013-0387OC on January 31, 2014
Internet address: www.atsjournals.org

exposure leads to functional, structural, neural, vascular, and immunological alterations in airways (10–16). This airway remodeling indicates that environmental insults early in life can have life-long deleterious effects on lung function and may lead to chronic asthma symptoms.

Airway hyperresponsiveness (AHR), a functional hallmark of asthma, is assessed with a bronchoprovocation test (17). The presence of AHR after O_3 and HDMA exposure indicates that airway function has been compromised. In humans, nonhuman primates, and other models of asthma, O_3 and HDMA exposure has been shown to increase AHR (18–21).

Recent literature suggests that serotonin (5-HT) plays a role in the asthma response (22–24). Animal studies show that 5-HT increases airway resistance and O_3 + HDMA exposure of infant monkeys results in 5-HT–positive cells within airway epithelia (25–27). Patients with asthma have higher 5-HT plasma levels, which are inversely correlated with lung function, and drug treatments that lower plasma 5-HT decrease symptom severity and improve lung function (6, 28, 29). Our lab has shown that exposure of O_3 + HDMA induces AHR and exacerbates 5-HT–mediated airway smooth muscle (ASM) contraction in a model of childhood asthma (18) and that the combined exposure of O_3 + HDMA results in alterations in 9 of 10 immune, structural, and functional end points, with six of the end points demonstrating greater than additive effects of O_3 or HDMA exposure alone (10). Studies have epidemiologically confirmed asthma persistence from childhood through adulthood, linking persistent symptoms to atopy, smoking, air pollution (including O_3), early age at onset of asthma, and airway remodeling (30–34).

To date, no study has examined the persistence of AHR and 5-HT enhancement of ASM contraction in a controlled setting using a model of childhood asthma. The aims of this project are (*1*) to determine if AHR and 5-HT–enhanced ASM contraction induced by O_3 + HDMA exposure persist after a prolonged recovery period in a filtered air (FA) environment and (*2*) to identify which 5-HT subtype receptors are responsible for driving the 5-HT response. Confirming the persistence of AHR caused by early-life exposure to O_3 + HDMA will help guide environmental policy and substantiate the need to mitigate exposure, especially in young populations. Associating a 5-HT–mediated mechanism with persistent AHR offers a novel therapeutic target for asthma treatment.

Rhesus monkeys were used because they have similar lung cellular morphology, airway architecture, and immunology and undergo a similar extensive period of postnatal development compared with humans (35–39). In addition to possessing all of the components of the intrapulmonary conducting airways that are altered in humans with asthma, rhesus monkeys display a similar progression of asthma pathophysiology and symptoms (11, 40). The sensitization protocol used induces the functional, immunologic, histological, and clinical characteristics that are used to diagnose allergic asthma (40).

Materials and Methods

Care of animals complied with the Institute of Laboratory Animal Resources and the American Association for Accreditation of Laboratory Animal Care (AAALAC). Procedures were approved by the University of California - Davis Institutional Animal Care and Use Committee (41). The University of California - Davis and the California National Primate Research Center are accredited by AAALAC.

General Protocol

Twelve 30-day-old, captive-born rhesus monkeys were randomly assigned to one of two groups: FA or O_3 plus HDMA (O_3 + HDMA). All animals were sensitized to HDMA and exposed to 11 episodes of FA or O_3 + HDMA as previously described (10, 18) (Figure 1). Exposures had a HDMA mass concentration averaging 7.05 ± 0.73 mg/m^3 and a mean O_3 concentration of 0.500 ± 0.005 ppm. Monkeys were killed with sodium pentobarbital (15 ml/kg). A distal tracheal portion was harvested and placed in modified Kreb's solution.

Airway Responsiveness Testing

At 3 years of age, airway resistance (R_{aw}) was measured during a histamine challenge and expressed as the concentration of histamine causing a 200% increase in Raw ($EC200R_{aw}$) (40).

Electrical Field Stimulation

Airway rings were suspended between platinum wire electrodes in tissue baths (Myobath; WPI Inc., Sarasota, FL) as previously described (18). Tension was measured via Fort 10 g transducers (WPI Inc.) and recorded with Powerlab Chart 5.1 software (ADInstruments, Colorado Springs, CO). Monophasic square-wave impulses (50 V, 4 Hz, 0.5 ms) were delivered for 30 seconds every 4 minutes until three consecutive stable responses were observed. Pulses were induced via S88 Stimulators (Grass Technologies, West Warwick, RI).

5-HT Concentration-Response Curves

Six rings from each animal were used to perform 5-HT concentration-response curves during electric field stimulation (EFS)-induced contractions.

Antagonist Concentration-Response Curves

5-HT concentration-response curves were performed in the presence of antagonists (Table 1).

The Effect of 5-HT_{1A}R Activation

Previous research identified an inhibitory pathway mediated through 5-HT_{1A} receptors (18). These analyses were reproduced.

Baseline Responses

Acetylcholine (ACh) concentration-response curves were performed (one control and one preincubated with 10 μM 5-HT). Voltage-response curves and frequency-response curves were performed on tracheal rings.

Concluding Experiments

Airway rings were exposed to 10 mM ACh to compare tension with the initial ACh concentration-response curves. The effect of atropine (1 μM) was evaluated to ensure muscarinic-mediated contractions. To verify that the responses were neurogenic, tissue was incubated in 3 μM tetrodotoxin before EFS. All drugs were purchased from Sigma-Aldrich Co. (St. Louis, MO).

Statistical Analysis

Results are expressed as mean ± SEM. Airway responsiveness data; between-group EC_{50}, EV_{50}, EF_{50}; and 5-HT direct effect values were analyzed using Student's *t* tests. Within-group 5-HT direct effects and the direct effect of 8-OH-DPAT were analyzed with paired-samples *t* tests.



Figure 1. Timeline of exposure protocol. FA, filtered air; HDMA, house dust mite allergen.

Concentration-responses were compared using repeated-measures ANOVAs. Tukey *post hoc* testing was used to identify the source of significance. The α level was set at 0.05. Significance was based on the adjusted *P* value. A one-way *t* test was used to assess the direct effect of 5-HT on ASM contraction based on previous findings that 5-HT constricts ASM.

Results

Airway Responsiveness

O_3 + HDMA exposure induced a significant increase in airway responsiveness when compared with FA controls, even with a prolonged 2.5-year recovery period in FA ($EC200R_{aw}$ FA = 14.43 ± 3.89 mg/ml; O_3 + HDMA = 4.88 ± 0.60 mg/ml; $P = 0.04$) (Figure 2).

5-HT Concentration Response

O_3 + HDMA exposure resulted in enhanced airway contractility in the presence of 5-HT, indicated by significantly increased EFS-induced ASM tension production when compared with FA animals at 100 μM 5-HT (FA = 308.5 ± 39.0%; O_3 + HDMA = 930.3 ± 97.4%; $P = 0.008$). All 5-HT concentrations in the O_3 + HDMA group produced significantly greater tension than the EFS-induced tension produced during their control response (EFS-induced contraction in the absence of 5-HT; $P < 0.05$), which was not the case in the FA group. In the FA group, none of the 5-HT concentrations elicited a contraction significantly greater than its control response ($P > 0.05$) (Figure 3). There was also an overall group effect, with the O_3 + HDMA group producing a significantly higher mean tension (as % of control EFS response) than the FA group (O_3 + HDMA = 378.0%; FA = 214.3%; $P < 0.006$).

Antagonist Concentration Response

In the O_3 + HDMA group, incubation with increasing concentrations of $5\text{-}HT_{2A}$ (ketanserin), $5\text{-}HT_3$ (ondansetron), or $5\text{-}HT_4$ (GR 113808) subtype receptor antagonists attenuated the tension induced by EFS at all 5-HT concentrations, indicating that these three receptors are involved in the ASM response to 5-HT (Figure 4).

The Effect of $5\text{-}HT_{1A}$ Receptor Activation

Addition of the $5\text{-}HT_{1A}$ receptor agonist 8-OH-DPAT significantly attenuated EFS-induced ASM contraction in a concentration-dependent manner (Figure 5A). This effect was seen in both the FA and O_3 + HDMA groups, indicating that exposure had no effect. The direct effect of $5\text{-}HT_{1A}$ receptor activation on ASM tension induced by 100 μM exogenous ACh was also evaluated. Concentrations of 10 and 100 μM 8-OH-DPAT significantly attenuated ACh-induced tension in both the FA and O_3 + HDMA groups. There was no between-group difference in the response, indicating that exposure had no effect on $5\text{-}HT_{1A}$ receptor activation (Figure 5B).

Direct Effect of 5-HT on ASM Tension

The addition of 10 μM 5-HT produced a small, but consistent, increase in ASM tension in the FA and O_3 + HDMA groups. In the FA group, tension increased from 0.992 ± 0.007 g to 1.204 ± 0.229 g ($P = 0.037$). This increase was just over 6% of the maximal response to ACh. In the O_3 + HDMA group, 10 μM 5-HT caused a tension increase amounting to 12.75% of the maximal ACh response (Figure 6A). When comparing the change in absolute tension between the FA and O_3 + HDMA groups, O_3 + HDMA exposure produced a significantly greater 5-HT–induced tension increase compared with the FA group (0.549 ± 0.146 g versus 0.211 ± 0.094 g) (Figure 6B). This indicates that 5-HT directly induces ASM contraction and that O_3 + HDMA exposure exacerbates this response.

Baseline ASM Response

Before 5-HT addition, frequency-response and voltage-response curves were performed. There was no difference in the voltage needed to induce 50% of maximum EFS tension (EV_{50}) between groups (EV_{50}, FA = 41.6 ± 2.5 V; O_3 + HDMA = 42.5 ± 4.4 V; $P > 0.05$). There was no significant difference in the frequency necessary to induce 50% of maximum EFS tension (EF_{50}) between groups (EV_{50}, FA = 9.6 ± 2.4 Hz; O_3 + HDMA = 7.1 ± 0.7 Hz;

Table 1. Summary of Antagonists

Drug	Receptor	Concentration Range (*μM*)	References
Ketanserin	5-HT2A	1, 10, 100	61, 62
Ondansetron	5-HT3	1, 10, 100	63, 64
GR 113808	5-HT4	1, 10, 100	65, 66



Figure 2. Airway responsiveness during histamine challenge. *The O_3 + HDMA group exhibited a significant increase in airway responsiveness when compared with FA (P = 0.04; n = 6). EC200R_{aw} is the effective concentration of histamine needed to induce a 200% increase in airway resistance. The lower the effective concentration, the more responsive the airway.

$P > 0.05$). This indicates that without exogenous 5-HT added to the tissue baths, the airway rings from the O_3 + HDMA animals and the FA animals responded similarly to EFS.

Concluding Experiments

Tissue response to 10 mM ACh at the conclusion of the experiment produced over 93% (1.442 g versus 1.541 g) of the tension seen at the beginning of the protocol, indicating adequate tissue viability throughout the testing. Atropine and tetrodotoxin completely attenuated EFS response, confirming that EFS-induced contractions were neurogenic of origin and induced by activation of cholinergic receptors on the ASM.

Discussion

Although persistent asthma symptoms have been linked to environmental O_3 and allergen exposure, no study to date has examined the persistent effect of O_3 + HDMA exposure in a model of childhood asthma. Our previous research showed that cyclical exposure to O_3 + HDMA from 1 to 6 months of life in allergic rhesus monkeys results in a hyperresponsive airway and in a 5-HT–mediated enhancement of ASM contraction (18). With the wealth of epidemiologic data supporting the negative effects of early-life exposure to O_3 and allergens, it makes sense to question whether or not the functional decrements seen with O_3 + HDMA exposure in our model of childhood asthma would persist if the animals were allowed a prolonged recovery in a FA environment (6, 42–44). This study confirms that O_3 + HDMA exposure induces persistent AHR and exacerbated 5-HT–mediated ASM contraction, even after a prolonged recovery period, in a model of childhood asthma.

Airway Responsiveness

AHR is a functional indicator of asthma. When comparing EC200R_{aw} between the O_3 + HDMA exposure and FA groups, the exposure group required a significantly lower dose (Figure 2). The AHR seen in the O_3 + HDMA group closely resembles that of our previous work using the same exposure protocol that did not allow for a prolonged recovery (18). This signifies that the functional decrement induced by O_3 + HDMA exposure seen after 5 months of exposure persists even after 2.5 years of recovery in a FA environment. The persistence of AHR after a prolonged recovery period underscores the deleterious effects of early-life exposure to O_3 + HDMA and that such exposure not only leads to acute pulmonary dysfunction in allergic individuals but induces chronic changes in airway function that remain after a long recovery period even when the environmental insult is no longer present.

Unlike previous studies (25, 45, 46) in which sensitivity to HDMA was maintained in the O_3 + HDMA group during recovery, persistent functional alterations were found in this study even though there was no attempt to ensure maintained HDMA sensitivity and the recovery period was extended from 6 to 30 months. The impact of this observation is even more significant when one considers that the exposure occurred during a period of rapid postnatal lung development and that the detrimental effects were still present at an age equivalent to preadolescence in humans. This reinforces the need to minimize children's exposures to air pollution and allergens during the extended postnatal maturation of the lungs, otherwise risking decrements in lung function lasting into adulthood, regardless of the presence of environmental insults.

5-HT Concentration-Response Curves

Not only did the pulmonary functional decrements induced by O_3 + HDMA exposure persist after the prolonged recovery period, but the 5-HT–mediated exacerbation of ASM contraction did as well (Figure 3). The persistence of a 5-HT mechanism with the functional decrements indicates that altered serotonergic signaling at the postganglionic nerve innervating ASM may play a role in the persistent AHR induced by O_3 + HDMA exposure. 5-HT has been implicated in asthma from clinical, inflammatory, immunologic, and neurogenic points of view (23, 28, 29, 47–52). It is well substantiated that 5-HT can enhance the neuronal release of ACh at nerve endings (53). Mechanistically, it is possible that an increase in the presence of 5-HT or an up-regulation of 5-HT receptors at the postganglionic nerve could induce exacerbated 5-HT–mediated ASM contraction, leading to AHR and contributing to chronic asthma symptoms. 5-HT has been shown to up-regulate thromboxane release, leading to AHR (22). Exposure to O_3 + HDMA induces the proliferation of 5-HT–containing cells in the airway epithelia (25), and 5-HT levels are increased in the bronchoalveolar lavage fluid of patients with asthma after allergen challenge (23). In mice, allergen challenge induces 5-HT release from platelets (23). These studies indicate a plausible mechanism for 5-HT contributing to AHR



Figure 3. Effect of serotonin (5-HT) concentration on airway contractility during electric field stimulation (EFS). *Tension production in O_3 + HDMA group is significantly greater than in the FA group at 100 μM 5-HT. †In the O_3 + HDMA group, tension production at each 5-HT concentration was greater than the control response. Control response is defined as the amount of tension produced via EFS before addition of 5-HT. There was no within-group effect seen in the FA group ($P > 0.05$; n = 6).



Figure 4. Effect of 5-HT concentration on airway contractility during EFS in the presence of 5-HT subtype receptor antagonists. (*A*) The 5-HT_{2A} receptor antagonist ketanserin (Ket). (*B*) The 5-HT_3 receptor antagonist ondansetron (Ond). (*C*) The 5-HT_4 receptor antagonist, GR 113808. *All concentrations of the receptor antagonist induced a significant reduction in tension at each 5-HT concentration when compared with concentration-response curve with 5-HT alone. †Administration of 10 and 100 μM of antagonist significantly reduced tension compared with the concentration-response curve with 5-HT alone. "% of control" response is defined as the amount of tension produced via EFS before addition of 5-HT or 5-HT receptor antagonist ($P < 0.05$; $n = 6$).

and offer possible sources of 5-HT in the asthmatic airway.

Antagonist Concentration-Response Curves

To identify the specific 5-HT subtype receptors involved in the 5-HT response in the O_3 + HDMA group, 5-HT concentration response curves where conducted in the presence of 5-HT_{2A}, 5-HT_3, and 5-HT_4 subtype receptor antagonists. These receptors were targeted due to previous experiments run by this group and an extensive review of literature (18, 27, 49, 54, 55). Separate incubation with 5-HT_{2A}, 5-HT_3, and 5-HT_4 subtype receptor antagonists significantly attenuated the ASM contractile response to 5-HT, indicating that these receptors play a prominent role in the O_3 + HDMA–induced enhancement of ASM contraction.

The Effect of 5-HT_{1A} Receptor Activation

As noted in our previous exposure study, a counterbalancing inhibitory 5-HT effect was seen, mediated through 5-HT_{1A} receptors (18). The 5-HT_{1A} receptor agonist 8-OH-DPAT attenuated any tissue response to EFS and was able to diminish the tension produced by exogenous ACh, indicating that these receptors exert their effect at the ASM, as opposed to inducing postganglionic neural inhibition. This inhibitory effect was seen in both the FA and O_3 + HDMA groups, with exposure having no effect. Although dysregulation of an inhibitory pathway could lead to AHR and enhanced ASM contraction, these results suggest that increased ASM contraction with 5-HT is due to up-regulation of an excitatory pathway rather than the down-regulation of an inhibitory pathway.

Direct Effect of 5-HT on ASM Tension

O_3 + HDMA exposure enhanced the direct effect of 5-HT on ASM (Figure 6). 5-HT has been shown to directly contract ASM in multiple species (56, 56–58). The



Figure 5. (*A*) Effect of the 5-HT$_{1A}$ agonist 8-OH-DPAT on airway contractility during EFS. *EFS-induced tension is significantly less than within-group EFS control contraction before agonist addition. "% of control response" is defined as the amount of tension produced via EFS before addition of 5-HT or 5-HT receptor agonist. There was no difference in response between groups. (*B*) Direct effect of 8-OH-DPAT on airway smooth muscle (ASM) precontracted with 100 μM ACh. *ASM tension is significantly less than within-group control after 10 minutes of incubation with agonist. †Tension at 100 μM 5-HT is significantly less than within-group tension at 10 μM 5-HT. There was no difference in ASM tension between groups ($P > 0.05$; $n = 6$).

enhancement of 5-HT's ability to contract ASM is consistent with recent research identifying that a similar exposure protocol in rhesus monkeys induces an up-regulation of 5-HT receptor expression on ASM (59).

Although a functional study of this nature using EFS on whole excised airway tissue allows insight into the role of 5-HT in ASM function and AHR in a model of childhood allergic asthma, the limitations of such an experimental preparation must be acknowledged. Pharmacologic identification of receptor subtypes is common practice, but one must be careful when drawing conclusions. We attempted to use the most selective antagonists available, but, due to the variance of published receptor affinities, quantitative rank-order comparison of the contributions of each receptor subtype could not be established. Therefore, it was deemed imprudent to make assumptions regarding the relative contribution of each identified 5-HT receptor subtype (2–4) that was shown to be involved in the serotonergic enhancement of ASM contraction in the exposed animals. Current immunohistochemical studies are underway to identify which receptor subtypes are present at the ganglia and terminal axon of cholinergic nerves in FA and exposed monkeys.

This study focused on a conducting airway site located in the middle to lower trachea. Previous research shows that vascular remodeling in HDMA-exposed airways is generation specific (60). It is possible that O_3 + HDMA exposure may have differential effects along segments of the tracheobronchial tree. Studies evaluating ASM function at alternate airway generations could assess whether



Figure 6. Direct effect of 5-HT on ASM tension. (*A*) *Addition of 10 μM 5-HT induced a significant increase in ASM compared with the within-group baseline tension. PRE 5-HT, tissue at baseline tension of 1.0 g before addition of 5-HT; POST 5-HT, tissue tension after addition of 10 μM 5-HT. (*B*) †5-HT–induced tension increase was significantly greater in the O_3 + HDMA group than in the FA group ($P < 0.05$; $n = 6$).

exposure effects are widespread and consistent throughout conducting airways. Also, studies examining the intensity and longevity of the persistence of AHR and enhanced ASM contraction at different time points of exposure and recovery could help identify a critical window during postnatal lung development in which the airway is most susceptible to environmental toxicant damage.

This study did not use strategies to differentiate between responses due to HDMA-associated immune responses or reactive oxygen species formation via O_3 exposure. Previous research has shown a synergistic effect of O_3 + HDMA exposure, with O_3 amplifying the allergic, structural, and neural remodeling effects of HDMA sensitization and inhalation (10, 14, 25). Also, previous work has shown that immediately after 6 months of exposure to HDMA, O_3, or O_3 + HDMA, similar 5-HT–induced increases in neurally mediated ASM contractions were seen in all the groups (18). The common factor in all of these exposures is inflammation, whether it was induced via an HDMA-driven immune response or reactive oxygen species production via O_3 exposure. This experimental design did not allow us to differentiate between immune versus oxidant-induced inflammation, but this is a viable avenue for future research.

Further evaluation linking histological and structural changes to alterations in airway function and 5-HT handling will bridge a critical gap in our proposed model. Future research could also evaluate the effectiveness of 5-HT receptor antagonists at reversing AHR in whole animal studies. This study focused on the persistence of the combined effect of O_3 + HDMA exposure on AHR and 5-HT enhancement of ASM contraction and did not investigate the effect of exposure to each environmental insult separately, so the individual contributions of O_3 or HDMA to persistence cannot be addressed.

In conclusion, this study verifies for the first time that combined exposure to two recognized environmental contributors to asthma, O_3 and HDMA, induce prolonged decrements in lung function and lead to a 5-HT–mediated exacerbation of ASM contraction in a model of childhood asthma. These hallmarks of asthma—AHR and enhanced ASM contraction—persisted even after exposure to O_3 + HDMA had been discontinued for 2.5 years. This study also identified three 5-HT subtype receptors that contribute to the enhanced ASM contractile response (5-HT_{2A}, 5-HT_3, and 5-HT_4). These findings substantiate the need to minimize exposure of young individuals to known environmental contributors to asthma during critical periods of lung maturation because damage inflicted during these times can contribute to prolonged asthma symptoms. The identification of a persistent 5-HT–mediated enhanced ASM contraction may identify novel therapeutic targets for pharmacological intervention in the treatment of childhood asthma. ■

Author disclosures are available with the text of this article at www.atsjournals.org.

References

1. Bloom BCR, Freeman G. Summary health statistics for U.S. children: national health interview survey, 2011. Hyattsville, MD: Department of Health and Human Services; 2012.
2. Krenitsky-Korn S. High school students with asthma: attitudes about school health, absenteeism, and its impact on academic achievement. *Pediatr Nurs* 2011;37:61–68.
3. YoussefAgha AH, Jayawardene WP, Lohrmann DK, El Afandi GS. Air pollution indicators predict outbreaks of asthma exacerbations among elementary school children: integration of daily environmental and school health surveillance systems in Pennsylvania. *J Environ Monit* 2012;14:3202–3210.
4. Rosenlund M, Forastiere F, Porta D, De Sario M, Badaloni C, Perucci CA. Traffic-related air pollution in relation to respiratory symptoms, allergic sensitisation and lung function in schoolchildren. *Thorax* 2009;64: 573–580.
5. Gielen MH, van der Zee SC, van Wijnen JH, van Steen CJ, Brunekreef B. Acute effects of summer air pollution on respiratory health of asthmatic children. *Am J Respir Crit Care Med* 1997;155:2105–2108.
6. Bernstein DI. Traffic-related pollutants and wheezing in children. *J Asthma* 2012;49:5–7.
7. Schelegle ES, Morales CA, Walby WF, Marion S, Allen RP. 6.6-hour inhalation of ozone concentrations from 60 to 87 parts per billion in healthy humans. *Am J Respir Crit Care Med* 2009;180: 265–272.
8. Strickland MJ, Darrow LA, Klein M, Flanders WD, Sarnat JA, Waller LA, Sarnat SE, Mulholland JA, Tolbert PE. Short-term associations between ambient air pollutants and pediatric asthma emergency department visits. *Am J Respir Crit Care Med* 2010; 182:307–316.
9. McConnell R, Berhane K, Gilliland F, London SJ, Islam T, Gauderman WJ, Avol E, Margolis HG, Peters JM. Asthma in exercising children exposed to ozone: a cohort study. *Lancet* 2002;359:386–391.
10. Schelegle ES, Miller LA, Gershwin LJ, Fanucchi MV, Van Winkle LS, Gerriets JE, Walby WF, Mitchell V, Tarkington BK, Wong VJ, *et al*. Repeated episodes of ozone inhalation amplifies the effects of allergen sensitization and inhalation on airway immune and structural development in Rhesus monkeys. *Toxicol Appl Pharmacol* 2003;191: 74–85.
11. Evans MJ, Fanucchi MV, Baker GL, Van Winkle LS, Pantle LM, Nishio SJ, Schelegle ES, Gershwin LJ, Miller LA, Hyde DM, *et al*. Atypical development of the tracheal basement membrane zone of infant rhesus monkeys exposed to ozone and allergen. *Am J Physiol Lung Cell Mol Physiol* 2003;285:L931–L939.
12. Fanucchi MV, Plopper CG, Evans MJ, Hyde DM, Van Winkle LS, Gershwin LJ, Schelegle ES. Cyclic exposure to ozone alters distal airway development in infant rhesus monkeys. *Am J Physiol Lung Cell Mol Physiol* 2006;291:L644–L650.
13. Joad JP, Kott KS, Bric JM, Peake JL, Plopper CG, Schelegle ES, Gershwin LJ, Pinkerton KE. Structural and functional localization of airway effects from episodic exposure of infant monkeys to allergen and/or ozone. *Toxicol Appl Pharmacol* 2006;214:237–243.
14. Larson SD, Schelegle ES, Walby WF, Gershwin LJ, Fanuccihi MV, Evans MJ, Joad JP, Tarkington BK, Hyde DM, Plopper CG. Postnatal remodeling of the neural components of the epithelial-mesenchymal trophic unit in the proximal airways of infant rhesus monkeys exposed to ozone and allergen. *Toxicol Appl Pharmacol* 2004;194:211–220.
15. Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, *et al*. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. *Vaccine* 2009;28:452–462.
16. Avdalovic MV, Tyler NK, Putney L, Nishio SJ, Quesenberry S, Singh PJ, Miller LA, Schelegle ES, Plopper CG, Vu T, *et al*. Ozone exposure during the early postnatal period alters the timing and pattern of alveolar growth and development in nonhuman primates. *Anat Rec (Hoboken)* 2012;295:1707–1716.
17. Backer V, Groth S, Dirksen A, Bach-Mortensen N, Hansen KK, Laursen EM, Wendelboe D. Sensitivity and specificity of the histamine challenge test for the diagnosis of asthma in an unselected sample of children and adolescents. *Eur Respir J* 1991;4:1093–1100.

18. Moore BD, Hyde D, Miller L, Wong E, Frelinger J, Schelegle ES. Allergen and ozone exacerbate serotonin-induced increases in airway smooth muscle contraction in a model of childhood asthma. *Respiration* 2012;3:529–542.
19. Schulze J, Voss S, Zissler U, Rose MA, Zielen S, Schubert R. Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge. *Respir Res* 2012;13: 78.
20. Bao A, Liang L, Li F, Zhang M, Zhou X. Effects of acute ozone exposure on lung peak allergic inflammation of mice. *Front Biosci (Landmark Ed)* 2013;18:838–851.
21. Scannell C, Chen L, Aris RM, Tager I, Christian D, Ferrando R, Welch B, Kelly T, Balmes JR. Greater ozone-induced inflammatory responses in subjects with asthma. *Am J Respir Crit Care Med* 1996;154:24–29.
22. Montano LM, Carbajal V, Vargas MH, Garcia-Hernandez LM, Diaz-Hernandez V, Checa M, Barajas-Lopez C. Histamine, carbachol, and serotonin induce hyperresponsiveness to atp in guinea pig tracheas: Involvement of cox-2 pathway. *Pflugers Arch* 2013;465: 1171–1179.
23. Dürk T, Duerschmied D, Müller T, Grimm M, Reuter S, Vieira RP, Ayata K, Cicko S, Sorichter S, Walther DJ, *et al*. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. *Am J Respir Crit Care Med* 2013;187: 476–485.
24. Cooper PR, Zhang J, Damera G, Hoshi T, Zopf DA, Panettieri RA, Jr. C-027 inhibits ige-mediated passive sensitization bronchoconstriction and acts as a histamine and serotonin antagonist in human airways. *Allergy Asthma Proc* 2011;32:359–365.
25. Kajekar R, Pieczarka EM, Smiley-Jewell SM, Schelegle ES, Fanucchi MV, Plopper CG. Early postnatal exposure to allergen and ozone leads to hyperinnervation of the pulmonary epithelium. *Respir Physiol Neurobiol* 2007;155:55–63.
26. Aizawa H, Takata S, Shigyo M, Matsumoto K, Inoue H, Hara N. N-omega-nitro-l-arginine methyl ester increases airway responsiveness to serotonin but not to acetylcholine in cats in vivo. *Respiration* 2001; 68:286–291.
27. Segura P, Vargas MH, Cordoba-Rodriguez G, Chavez J, Arreola JL, Campos-Bedolla P, Ruiz V, Garcia-Hernandez LM, Mendez C, Montano LM. Role of 5-ht2a, 5-ht4 and 5-ht7 receptors in the antigen-induced airway hyperresponsiveness in guinea-pigs. *Clin Exp Allergy* 2010;40:327–338.
28. Lechin F, van der Dijs B, Orozco B, Lechin M, Lechin AE. Increased levels of free serotonin in plasma of symptomatic asthmatic patients. *Ann Allergy Asthma Immunol* 1996;77:245–253.
29. Lechin F, van der Dijs B, Orozco B, Jara H, Rada I, Lechin ME, Lechin AE. Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study. *Clin Pharmacol Ther* 1998;64:223–232.
30. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. *N Engl J Med* 2003;349:1414–1422.
31. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, Sears MR. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. *Am J Respir Crit Care Med* 2002;165:1480–1488.
32. Phelan PD, Robertson CF, Olinsky A. The melbourne asthma study: 1964–1999. *J Allergy Clin Immunol* 2002;109:189–194.
33. Wright RJ, Brunst KJ. Programming of respiratory health in childhood: influence of outdoor air pollution. *Curr Opin Pediatr* 2013;25: 232–239.
34. Al-Hegelan M, Tighe RM, Castillo C, Hollingsworth JW. Ambient ozone and pulmonary innate immunity. *Immunol Res* 2011;49:173–191.
35. Evans MJ, Fanucchi MV, Plopper CG, Hyde DM. Postnatal development of the lamina reticularis in primate airways. *Anat Rec (Hoboken)* 2010;293:947–954.
36. Plopper CG, Heidsiek JG, Weir AJ, George JA, Hyde DM. Tracheobronchial epithelium in the adult rhesus monkey: a quantitative histochemical and ultrastructural study. *Am J Anat* 1989;184:31–40.
37. Plopper CG, Alley JL, Weir AJ. Differentiation of tracheal epithelium during fetal lung maturation in the rhesus monkey Macaca mulatta. *Am J Anat* 1986;175:59–71.
38. Plopper C, St George J, Cardoso W, Wu R, Pinkerton K, Buckpitt A. Development of airway epithelium. Patterns of expression for markers of differentiation. *Chest* 1992;101(Suppl):2S–5S.
39. Plopper CG, Weir AJ, Nishio SJ, Cranz DL, St George JA. Tracheal submucosal gland development in the rhesus monkey, Macaca mulatta: ultrastructure and histochemistry. *Anat Embryol (Berl)* 1986; 174:167–178.
40. Schelegle ES, Gershwin LJ, Miller LAC, Fanucchi MV, Van Winkle LS, Gerriets JP, Walby WF, Omlor AM, Buckpitt AR, Tarkington BK, *et al*. Allergic asthma induced in rhesus monkeys by house dust mite (Dermatophagoides farinae). *Am J Pathol* 2001;158:333–341.
41. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. Washington, DC: National Academies Press; 2011.
42. Brunst KJ, Ryan PH, Lockey JE, Bernstein DI, McKay RT, Khurana Hershey GK, Villareal M, Biagini Myers JM, Levin L, Burkle J, Evans S, Lemasters GK. Unraveling the relationship between aeroallergen sensitization, gender, second-hand smoke exposure, and impaired lung function. *Pediatr Allergy Immunol* 2012;23:479–487.
43. Celedón JC, Milton DK, Ramsey CD, Litonjua AA, Ryan L, Platts-Mills TA, Gold DR. Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood. *J Allergy Clin Immunol* 2007; 120:144–149.
44. Bateson TF, Schwartz J. Children's response to air pollutants. *J Toxicol Environ Health A* 2008;71:238–243.
45. Evans MJ, Fanucchi MV, Baker GL, Van Winkle LS, Pantle LM, Nishio SJ, Schelegle ES, Gershwin LJ, Miller LA, Hyde DM, *et al*. The remodelled tracheal basement membrane zone of infant rhesus monkeys after 6 months of recovery. *Clin Exp Allergy* 2004;34: 1131–1136.
46. Plopper CG, Smiley-Jewell SM, Miller LA, Fanucchi MV, Evans MJ, Buckpitt AR, Avdalovic M, Gershwin LJ, Joad JP, Kajekar R, *et al*. Asthma/allergic airways disease: does postnatal exposure to environmental toxicants promote airway pathobiology? *Toxicol Pathol* 2007;35:97–110.
47. Idzko M, Panther E, Stratz C, Müller T, Bayer H, Zissel G, Dürk T, Sorichter S, Di Virgilio F, Geissler M, *et al*. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. *J Immunol* 2004;172:6011–6019.
48. Dupont L, Pype J, Demedts M, De Leyn P, Deneffe G, Verleden G. The effects of 5-ht on cholinergic contraction in human airways in vitro. *Eur Respir J* 1999;14:642–649.
49. Takahashi T, Ward JK, Tadjkarimi S, Yacoub MH, Barnes PJ, Belvisi MG. 5-Hydroxytryptamine facilitates cholinergic bronchoconstriction in human and guinea pig airways. *Am J Respir Crit Care Med* 1995; 152:377–380.
50. Szarek JL, Zhang JZ, Gruetter CA. Mechanisms of 5-hydroxytryptamine-induced contraction of isolated rat intrapulmonary bronchi. *Pulm Pharmacol* 1995;8:273–281.
51. Cutz E, Yeger H, Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. *Pediatr Dev Pathol* 2007;10:419–435.
52. Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. *J Allergy Clin Immunol* 2007;119:498–499.
53. Fink KB, Göthert M. 5-HT receptor regulation of neurotransmitter release. *Pharmacol Rev* 2007;59:360–417.
54. Cazzola M, Assogna G, Lucchetti G, Cicchitto G, D'Amato G. Effect of ketanserin, a new blocking agent of the 5-HT2 receptor, on airway responsiveness in asthma. *Allergy* 1990;45:151–153.
55. Matera MG, De Santis D, D'Agostino B, Pallotta M, Vacca C, Cazzola M, Rossi F. Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction. *Immunopharmacology* 1995;29:73–78.
56. Buckner CK, Dea D, Liberati N, Krell RD. Guinea pig pulmonary responses to serotonin (5-HT) and related agonists. *Ann N Y Acad Sci* 1991;629:392–393.
57. Doucet MY, Jones TR, Ford-Hutchinson AW. Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoids, and leukotrienes in vitro. *Can J Physiol Pharmacol* 1990;68:379–383.

58. Seehase S, Schlepütz M, Switalla S, Mätz-Rensing K, Kaup FJ, Zöller M, Schlumbohm C, Fuchs E, Lauenstein HD, Winkler C, *et al*. Bronchoconstriction in nonhuman primates: a species comparison. *J Appl Physiol (1985)* 2011;111:791–798.
59. Murphy SR, Schelegle ES, Miller LA, Hyde DM, Van Winkle LS. Ozone exposure alters serotonin and serotonin receptor expression in the developing lung. *Toxicol Sci* 2013;134:168–179.
60. Avdalovic MV, Putney LF, Schelegle ES, Miller L, Usachenko JL, Tyler NK, Plopper CG, Gershwin LJ, Hyde DM. Vascular remodeling is airway generation-specific in a primate model of chronic asthma. *Am J Respir Crit Care Med* 2006;174:1069–1076.
61. Frishman WH, Grewall P. Serotonin and the heart. *Ann Med* 2000;32:195–209.
62. Ju JM, Hwang JH, Piao LH, Park HW, Park JS, Shin DH, Cho JG, Kim KK, Kim JH. Ketanserin, a 5-HT2 antagonist, directly inhibits the ATP-sensitive potassium channel in mouse ventricular myocytes. *J Cardiovasc Pharmacol* 2006;47:96–102.
63. Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. *CNS Drug Rev* 2001;7:199–213.
64. Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE, *et al*. Development of high-affinity 5-HT3 receptor antagonists: 1. Initial structure-activity relationship of novel benzamides. *J Med Chem* 1992;35:895–903.
65. Gale JD, Grossman CJ, Whitehead JW, Oxford AW, Bunce KT, Humphrey PP. GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. *Br J Pharmacol* 1994;111: 332–338.
66. Pindon A, van Hecke G, van Gompel P, Lesage AS, Leysen JE, Jurzak M. Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins. *Mol Pharmacol* 2002;61:85–96.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Brian

2. Surname (Last Name)
Moore

3. Date
27-January-2014

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name
Edward Schelegle

5. Manuscript Title
Persistence of serotonergic enhancement of airway response in a model of childhood asthma

6. Manuscript Identifying Number (if you know it)
Red-2013-0387OC.R1

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Moore has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Emily
2. Surname (Last Name): Wong
3. Date: 27-January-2014
4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Schelegle

5. Manuscript Title: Persistence of serotonergic enhancement of airway response in a model of childhood asthma
6. Manuscript Identifying Number (if you know it): Red-2013-0387OC.R1

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Moore has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Lisa

2. Surname (Last Name)
Miller

3. Date
27-January-2014

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name
Edward Schelegle

5. Manuscript Title
Persistence of serotonergic enhancement of airway response in a model of childhood asthma

6. Manuscript Identifying Number (if you know it)
Red-2013-0387OC.R1

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Moore has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
Edward

2. Surname (Last Name)
Schelegle

3. Date
27-January-2014

4. Are you the corresponding author? ☑ Yes ☐ No

5. Manuscript Title
Persistence of serotonergic enhancement of airway response in a model of childhood asthma

6. Manuscript Identifying Number (if you know it)
Red-2013-0387OC.R1

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Schelegle has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Dallas
2. Surname (Last Name): Hyde
3. Date: 25-January-2014
4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Brian D. Moore

5. Manuscript Title: Persistence of serotonergic enhancement of airway response in a model of childhood asthma
6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Hyde has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Persistence of serotonergic enhancement of airway response in a model of childhood asthma

Brian D. Moore, Dallas M. Hyde, Lisa A. Miller, Emily M. Wong and Edward S. Schelegle

ONLINE DATA SUPPLEMENT

EXPANDED METHODS

Care and housing of animals complied with provisions of the Institute of Laboratory Animal Resources and conformed to practices established by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Procedures were approved by the UC Davis Institutional Animal Care and Use Committee, and followed the Guide to the Care and Use of Laboratory Animals [(US), 2011 #1236]. UC Davis and the California National Primate Research Center are accredited by AAALAC.

General protocol: Twelve captive-born rhesus monkeys (Macaca mulatta) were used in this study. 30-day old monkeys were randomly assigned to one of two exposure groups (*n*=6/group): Filtered air (FA) or ozone plus house dust mite allergen (O_3 + HDMA). All animals were sensitized to HDMA and each group was exposed to 11 episodes of FA or O_3 + HDMA as previously described [Wilson, 1984 #768;Schelegle, 2001 #742] (fig. 1). Exposures had a total HDMA mass concentration averaging 7.05 $\pm$ 0.73 mg/m^3 and a mean O_3 concentration of 0.500 $\pm$ 0.005 ppm. Monkeys were euthanized with intravenous sodium pentobarbital (15ml/kg). A distal tracheal portion was harvested and placed in modified Kreb's solution (NaCl 118 mM, KCl 5.4 mM, $NAHCO_3$ 25 mM, dextrose 11.1 mM, Na_2HPO_4 1 mM, $MgSO_4$ 1.2 mM, CaCl 1.9 mM).

Allergen sensitization protocol and procedures: At weeks 1, 3 and 7, animals were given a 1.0cc injection of Der p 1 (0.5 ug)/Der p 2(0.25 ug) in 10 mg alum placed in the upper back SQ. During week 1, animals were given a 0.1cc injection of Infanrix in the thigh IM. At weeks 2, 4 and 8 HDMA intranasal was injected into each nostril consisting 25 ug total Der p (whole extract) in PBS. At week 15 the animals received a 1.0cc injection of 1 ug Der p 1 + 0.5 ug Der p 2 in 10 mg Alum in the upper back SQ.

Intradermal skin testing: Skin tests were done at 7, 12, and 22 weeks. Monkeys were anesthetized with ketamine hydrochloride and hair was clipped from an area of the thorax. Three intradermal injections (0.1 ml) of PBS containing HDMA (1:000 w/v), histamine (1:1000), or diluent alone were observed for 30 min and wheal diameters were measured after 20 min. A skin test was positive if the diameter of the wheal formed in response to HDMA was greater than or equal to a length halfway between the diameters of the wheal produced by the diluent (negative control) and histamine (positive control) [Schelegle, 2001 #742;Schelegle, 2003 #28].

Airway responsiveness testing: At 3 years of age, airway resistance was measured during a histamine challenge and results were expressed as the concentration of histamine resulting in a 200% increase in airway resistance from baseline ($EC200R_{aw}$). Methods followed those described by Schelegle [Schelegle, 2001 #742].

Electrical field stimulation: Airway rings were suspended between platinum wire electrodes and placed into tissue baths (Myobath, WPI Inc., Sarasota, FL, USA) containing modified Kreb's solution with indomethacin (10 uM), phentolamine (0.1 uM), ICI 118,551 (0.1 uM), and hexamethonium (1 uM) to isolate cholinergic signaling at post-ganglionic nerves. Tissue was equilibrated under 1 gram of tension for 90 minutes and maintained at this resting baseline tension throughout experiment. Tension was measured via Fort 10g transducers (WPI Inc., Sarasota, FL, USA) and recorded with Powerlab Chart 5.1 software (ADInstruments, Colorado Springs, CO, USA). During equilibration, tissue was incubated with capsaicin (10 uM) for 30 minutes to deplete sensory nerves of endogenous tachykinins. Tissue baths were maintained at 37° C and continuously bubbled with 5% CO_2 in O_2. Monophasic square-wave impulses at 50 V

and frequency of 4 Hz with duration of 0.5 ms were delivered for 30 seconds every 4 minutes until 3 consecutive stable responses. Pulses were induced via S88 Stimulators (Grass Technologies, West Warwick, RI, USA).

5-HT concentration-response: Six rings from each animal were utilized to perform concurrent concentration-response curves with 5-HT during EFS-induced ASM contractions.

Antagonist concentration-response: 5-HT concentration-response curves were performed in the presence of three concentrations of each 5-HT subtype receptor antagonist (table 1).

Table 1. Summary of antagonists

Drug	Receptor	Concentration Range (uM)	References
Ketanserin	5-HT2A	1, 10, 100	[Frishman, 2000 #802;Ju, 2006 #818]
Ondansetron	5-HT3	1, 10, 100	[Ye, 2001 #819;Youssefyeh, 1992 #1153]
GR 113808	5-HT4	1, 10, 100	[Gale, 1994 #1453;Pindon, 2002 #1456]

The effect of 5-HT$_{1A}$ receptor activation: Our previous research identified a counterbalancing inhibitory pathway mediated through 5-HT$_{1A}$ receptors that are located directly on ASM, which is unaffected by exposure [Moore, 2012 #1521]. These analyses were reproduced in this study, to confirm that a prolonged recovery did not alter this mechanism.

Baseline responses: Two acetylcholine (ACh) concentration-response curves were performed; one control and one pre-incubated with 10 uM 5-HT. The direct effect of addition of 10 uM 5-HT was recorded. A voltage-response curve (VRC) and

frequency-response curve (FRC) were performed on each tracheal ring to evaluate baseline differences between groups during EFS-induced contraction.

Concluding experiments: Airway rings were exposed to 10 mM Ach and the tension produced compared to the tension achieved with 10 mM ACh during the initial ACh concentration-response curves. To ensure that EFS-induced contractions were due to activation of muscarinic receptors located on the ASM, the EFS response following the addition of atropine (1 uM) was evaluated. To verify that the responses were neurogenic, tissue was incubated in 3 uM tetrodotoxin (TTX) prior to EFS. All drugs were purchased from Sigma-Aldrich Company (St. Louis, MO, USA).

Statistical analysis: Results are expressed as mean $\pm$ standard error of the mean. Airway responsiveness data, between-group EC_{50}, EV_{50}, EF_{50}, and 5-HT direct effect values were analyzed using Student's T-Test. Within-group 5-HT direct effects were analyzed with paired-samples T-Tests. 5-HT, agonist, and antagonist concentration-response trials were compared using repeated-measures (concentration) ANOVAs. Tukey post-hoc testing was utilized to identify the source of significance between the means of the subgroups. During antagonist concentration-response curves, the baseline tension was adjusted by subtracting the control EFS response from the EFS response after incubation with the antagonist. When evaluating the direct effect of 8-OH-DPAT on tissue pre-contracted with 100 uM ACh, each tissue served as it's own control and a 2-sample paired t-test design was employed. The α level was set at 0.05 for all experiments, and if multiple post hoc tests were performed, significance was based on the adjusted p value. A one-way T-Test was used to assess the direct effect of 5-HT on ASM

contraction, based on previous findings by this group and published research indicating that 5-HT constricts ASM.